KPRX - Kiora Pharmaceuticals, Inc. News

Sectors

KPRX

Kiora Pharmaceuticals, Inc.

2.53

1 x 2.57

1 x 2.63

bid

ask

0.00

0.00%

10:02 AM

timesize

Ytd	28.43%
1y	-16.50%

2.52

day range

2.52

1.76

52 week range

3.15

Open	2.52	Prev Close	2.53	Low	2.52	High	2.52	Mkt Cap	11.21M
Vol	101.00	Avg Vol	38.54K	EPS	-2.71	P/E	-0.93	Forward P/E	-1.48
Beta	-0.40	Short Ratio	0.27	Inst. Own	48.34%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-11	50-d Avg	2.58	200-d Avg	2.32	1yr Est	40.50

KPRX News

newsfilecorp.com

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX)

benzinga.com

Kiora Pharmaceuticals Released Preclinical Data Showing That KIO-300 Significantly Suppressed Seizur

Kiora Pharmaceuticals (NASDAQ:KPRX) today announced preclinical data showing that KIO-300, part of t

newsfilecorp.com

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Pre

Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epil

benzinga.com

Kiora Pharmaceuticals Files Prospectus For Offering 11.797M Common Stock On Behalf Of Selling Shareh

https://www.sec.gov/Archives/edgar/data/1372514/000137251426000050/s-3xapril2026.htm

benzinga.com

Kiora Pharmaceuticals Q1 EPS $(0.58) Beats $(0.71) Estimate

Kiora Pharmaceuticals (NASDAQ:KPRX) reported quarterly losses of $(0.58) per share which beat the an

newsfilecorp.com

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today r

newsfilecorp.com

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase

Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) toda

defenseworld.net

Financial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)

Cronos Group (NASDAQ: CRON - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Rep

benzinga.com

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

newsfilecorp.com

Kiora Pharmaceuticals Announces Management Team Changes

Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX)

benzinga.com

Kiora Pharmaceuticals Q4 EPS $(1.60) Misses $(0.67) Estimate

Kiora Pharmaceuticals (NASDAQ:KPRX) reported quarterly losses of $(1.60) per share which missed the

newsfilecorp.com

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Di

Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX

newsfilecorp.com

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: K

defenseworld.net

Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN)

Stevanato Group (NYSE: STVN - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Re

newsfilecorp.com

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) ha

benzinga.com

Kiora Pharmaceuticals Secures New US Patent to Expand Delivery Options for Eye Drug KIO-104

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) today announced that the U.S. Patent and Trademark Office

newsfilecorp.com

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of

Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KP

benzinga.com

12 Health Care Stocks Moving In Friday's After-Market Session

benzinga.com

Earnings Scheduled For November 7, 2025

newsfilecorp.com

Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Activel

Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KP

benzinga.com

Kiora Pharmaceuticals Joins Global Genes' RARE-X Vision Consortium, A Corporate-Nonprofit Initiative

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) and Global Genes today announced that Kiora has joined Glo

prnewswire.com

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New

ENCINITAS, Calif. and WASHINGTON D.C.

newsfilecorp.com

Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KP

benzinga.com

Kiora Pharmaceuticals Files For $100M Mixed Shelf Offering

https://www.sec.gov/Archives/edgar/data/1372514/000137251425000072/s-3xseptember2025.htm

benzinga.com

HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy

fool.com

Kiora (KPRX) Q2 Revenue Falls 100%

newsfilecorp.com

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active

Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX

newsfilecorp.com

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocula

Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX)

zacks.com

Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know

Kiora Pharmaceuticals (KPRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing o

benzinga.com

12 Health Care Stocks Moving In Thursday's After-Market Session

benzinga.com

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 729 companies set new 52-week lows.